Finland· FI-REL-REL55857
Lumoxiti
A moxetumomab pasudotox product containing moxetumomab pasudotox, registered in Finland by AstraZeneca AB.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Moxetumomab pasudotox
- Manufacturer
- AstraZeneca AB
- Country
- Finland (FI)
- ATC code
- L01FB02
- ATC class
- Moxetumomab pasudotox
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
28 interactions on record for moxetumomab pasudotox.
Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Moxetumomab pasudotox · interactions on record
28 records
- 17 severe
- 11 moderate
Most severe, free to view
- TemsirolimusL01EG01severe
- EverolimusL01EG02severe
- SirolimusL01EG04severe
- TemsirolimusL01XE09severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Moxetumomab pasudotox in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/61bf84ba-aaea-403e-a1af-25710d30aa5b GET /v1/drugs/61bf84ba-aaea-403e-a1af-25710d30aa5b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "kuiva-aine välikonsentraatiksi ja liuos infuusionestettä varten, liuos",
"route": null,
"ddd_unit": null,
"strength": "1 mg",
"atc_label": "moksetumomabi-pasudotoksi",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/20/1522/001-002",
"fimea_rel_id": "REL55857",
"authorised_at": "2021-02-08"
}See everything about moxetumomab pasudotox.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.